UY30974A1 - METHOD FOR TREATING PAIN MEDIATED BY CB2 RECEIVERS (II) - Google Patents

METHOD FOR TREATING PAIN MEDIATED BY CB2 RECEIVERS (II)

Info

Publication number
UY30974A1
UY30974A1 UY30974A UY30974A UY30974A1 UY 30974 A1 UY30974 A1 UY 30974A1 UY 30974 A UY30974 A UY 30974A UY 30974 A UY30974 A UY 30974A UY 30974 A1 UY30974 A1 UY 30974A1
Authority
UY
Uruguay
Prior art keywords
receivers
treating pain
pain mediated
subject
mediated
Prior art date
Application number
UY30974A
Other languages
Spanish (es)
Inventor
Mingde Xia
Kevin Paul Pavlick
Mark J Macielag
Christopher Flores
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30974(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY30974A1 publication Critical patent/UY30974A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invencion se refiere a un método para tratar, aliviar o evitar el dolor mediado por los receptores CB2 en un sujeto que lo necesita, cuyo método comprende administrar al sujeto una cantidad eficaz de un compuesto de la formula (i): o una forma del mismo, en el cual X1R1, X2R2, X3R3, X4R4, y X5R5 son como se definieron en la presente.The present invention relates to a method for treating, relieving or avoiding pain mediated by CB2 receptors in a subject in need thereof, whose method comprises administering to the subject an effective amount of a compound of the formula (i): or a form thereof, in which X1R1, X2R2, X3R3, X4R4, and X5R5 are as defined herein.

UY30974A 2007-03-21 2008-03-19 METHOD FOR TREATING PAIN MEDIATED BY CB2 RECEIVERS (II) UY30974A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89601707P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
UY30974A1 true UY30974A1 (en) 2008-09-30

Family

ID=39766330

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30974A UY30974A1 (en) 2007-03-21 2008-03-19 METHOD FOR TREATING PAIN MEDIATED BY CB2 RECEIVERS (II)

Country Status (13)

Country Link
EP (1) EP2139327A4 (en)
JP (1) JP2010522182A (en)
KR (1) KR20090120500A (en)
CN (1) CN101677555A (en)
AR (1) AR065801A1 (en)
AU (1) AU2008229265A1 (en)
CA (1) CA2681384A1 (en)
CL (1) CL2008000817A1 (en)
MX (1) MX2009010164A (en)
PE (1) PE20090551A1 (en)
TW (1) TW200904414A (en)
UY (1) UY30974A1 (en)
WO (1) WO2008115672A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090179A2 (en) 2010-12-30 2012-07-05 Lupin Limited Isoquinoline derivatives as cannabinoid receptor modulators
WO2012090177A2 (en) 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
WO2013005168A2 (en) 2011-07-05 2013-01-10 Lupin Limited Cannabinoid receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548212A (en) * 2003-12-29 2010-07-30 Sepracor Inc Pyrrole and pyrazole DAAO inhibitors
TW200602324A (en) * 2004-03-24 2006-01-16 Janssen Pharmaceutica Nv Tetrahydro-indazole cannabinoid modulators cross reference to related applications
FR2875230A1 (en) * 2004-09-13 2006-03-17 Sanofi Aventis Sa CONDENSED PYRAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
AU2006302659A1 (en) * 2005-09-23 2007-04-19 Janssen Pharmaceutica, N.V. Hexahydro cyclooctyl pyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators

Also Published As

Publication number Publication date
TW200904414A (en) 2009-02-01
JP2010522182A (en) 2010-07-01
EP2139327A1 (en) 2010-01-06
AU2008229265A1 (en) 2008-09-25
KR20090120500A (en) 2009-11-24
PE20090551A1 (en) 2009-05-16
AR065801A1 (en) 2009-07-01
MX2009010164A (en) 2009-10-12
CA2681384A1 (en) 2008-09-25
WO2008115672A1 (en) 2008-09-25
CL2008000817A1 (en) 2008-09-26
EP2139327A4 (en) 2011-06-15
CN101677555A (en) 2010-03-24

Similar Documents

Publication Publication Date Title
PA8841901A1 (en) ORGANIC COMPOUNDS
CL2019003798A1 (en) Methods to treat huntington's disease.
GT201400102A (en) 4-PHENYL-PYRIDINES REPLACED FOR THE TREATMENT OF DISEASES RELATED TO THE RECEIVER OF NK1
CR20110046A (en) USEFUL AMIDOPHENOXYINDAZOLS AS C-MET INHIBITORS
UY32110A (en) AMINOPIRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF A DISEASE
UY32111A (en) HETEROCICLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF A DISEASE
CO6341577A2 (en) OLIGONUCLEOTID ANTISENTIDO DIRECTED AGAINST THE GROWTH FACTOR OF CONNECTIVE FABRIC AND USES OF THE SAME
AR091837A1 (en) COMPOUNDS FOR DIRECTED IMMUNOTHERAPY
CO6341558A2 (en) NMDA RECEIVER ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
CO6430459A2 (en) PROLIN DERIVATIVES AS CATEPSIN INHIBITORS
ECSP10010518A (en) HYDROXIMETHYL PIRROLIDINS AS AGONISTS OF THE BETA 3 ADRENERGIC RECEIVER
NI201500094A (en) SUBSTITUTE COMPOUNDS FOR PYRROLOPYRIMIDINE, COMPOSITIONS OF THE SAME, AND METHODS OF TREATMENT THEREOF.
EA201290919A1 (en) INDASOLIC COMPOUNDS AND THEIR APPLICATION
CL2015001389A1 (en) Compositions and anthelmintic compounds and methods for using them.
UY33627A (en) COMPOUNDS TO TREAT NEURODEGENERATIVE DISEASES
CO6511220A2 (en) QUINAZOLINAS AS INHIBITORS OF THE IONIC CHANNELS OF POTASIO
ECSP12011815A (en) SYNTHETIC METHODS FOR ESPIRO-OXOINDOL COMPOUNDS
UY33271A (en) HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF A DISEASE
PE20210949A1 (en) AFUCOSILATED ANTI-FGFR2IIIB ANTIBODIES
GT201200004A (en) FUSIONATED IMIDAZOLS AND COMPOSITIONS THAT CONTAIN THEM FOR THE TREATMENT OF PARASITARY DISEASES, AS BY MALARIA EXAMPLE
PA8850801A1 (en) USEFUL COMPOUNDS TO INHIBIT CHK1
CO6351779A2 (en) SMALL MOLECULA INHIBITORS OF THE ANDROGEN RECEPTOR N-TERMINAL ACTIVATION
UA107562C2 (en) METHOD OF TREATMENT OF PSORIASIS
UY31162A1 (en) SPIROINDOLINES AS CHEMIOKIN RECEPTORS MODULATORS
UY30974A1 (en) METHOD FOR TREATING PAIN MEDIATED BY CB2 RECEIVERS (II)